October 9, 2019 09:35 AM EDTUpdated October 10, 04:33 AM
Deals
R&D

Part­ner Bay­er push­es Ion­is' an­tithrom­bot­ic drug in­to mid-stage de­vel­op­ment

Natalie Grover

Reporter

In 2015, when Io­n­is Phar­ma­ceu­ti­cals car­ried the ill-fat­ed name of Isis Phar­ma­ceu­ti­cals, it grant­ed Bay­er the li­cense to de­vel­op its pro­grams tar­get­ing Fac­tor XI …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times